J&J Stock Slumps Despite Strong Q3 Results, Healthcare Sector Weakness

Johnson & Johnson (J&J) exceeded market expectations for Q3, raising its sales forecast. However, shares fell more than 5% on Tuesday as the medical device segment underperformed.
The adjusted earnings per share of $2.59 surpassed the $2.53 estimate but declined 7.5% year-over-year. While pharmaceutical revenue grew 7.7% to $16.76 billion, representing about 66% of quarterly sales, medical device sales rose only 2.5% to $8.64 billion—missing the analyst forecast of $8.71 billion.
Key products like Tremfya for psoriasis and inflammatory bowel disease saw a 68.3% surge to nearly $2.4 billion, while Darzalex, a blood cancer treatment, reported $4.24 billion but fell short of the $4.4 billion analyst expectation.
CFO Joe Wolk attributed medical device underperformance to Gulf countries shifting defense budgets, European austerity policies, and price pressures from China. He noted demand remains intact in these regions. Meanwhile, Abiomed's heart pump division faces UK research questioning its efficacy in certain high-risk procedures.
Medical device sales grew 4.8% domestically but saw little change internationally. Boston Scientific, another medical device maker, reported a 49.5% loss as of early September 2026 due to downward guidance and an August cyberattack.
Analysts noted J&J's trading price near 20x earnings, up from previous 15-16x levels, suggesting potential overvaluation. The company plans to spin off its orthopedics division DePuy Synthes by mid-2027, favoring a spin-off over sale due to lower medical device valuations amid economic slowdowns.
Korean Source
This article is an English localization of a Korean-language crypto news report. Original headline: J&J 매도, 헬스케어 주 약세…제약주 버팀목?